Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Compliance Experts Advise Against Treating Minor Changes As ‘Planned Deviations’

Oct 05 2018

• By Bowman Cox

How to achieve compliant pharmaceutical manufacturing without resorting to oxymorons like 'planned deviations'

Additional Topics

United States Compliance Manufacturing Quality BioPharmaceutical

More from Compliance

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window